Keywords: asco, focuses, personalized, therapy, including, wild-type, kras
ASCO 2009 focuses on personalized therapy including wild-type KRAS testing
Article | 08 June 2009
This year's American Society of Clinical Oncology meeting was themed around "personalized therapy," encouraging the search for predictive biomarkers that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
